[68ga]ga-dota-cys-ath001
Primary Sclerosing Cholangitis
Explore 22 assets in Primary Sclerosing Cholangitis →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Antaros Medical
Modality
UNKNOWN
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06562361CT.gov A Microdose Trial Investigating Binding of [68Ga]Ga-DOTA-CYS-ATH001 in Healthy Subjects and Different Patient Groups. | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Sclerosing Cholangitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| [68ga]ga-dota-cys-ath001 (this asset) | Antaros Medical | Early P1 | C · 39 |
| Vancomycin | Tampere University Hospital | P4 | BB |
| Ursodeoxycholic Acid | Assistance Publique - Hôpitaux de Paris | P3 | BB |
| Elafibranor | Ipsen | P3 | B |
| Aldafermin | NGM Biopharmaceuticals, Inc | P2/3 | B |
| CM-101 CCL24 BLOCKING MONOCLONAL ANTIBODY | ChemomAb Ltd. | P2 | B |
| htd1801 | HighTide Biopharma Pty Ltd | P2 | B |
| Tretinoin | Yale University | P2 | B |
| Cilofexor | Gilead Sciences | P3 | B |
+42 more in the Primary Sclerosing Cholangitis cohort
Other indications for [68ga]ga-dota-cys-ath001
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatohepatitis | — | Early P1 | C · 39 |
| Crohn Disease | — | Early P1 | NR |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. [68ga]ga-dota-cys-ath001 in Primary Sclerosing Cholangitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/68gaga-dota-cys-ath001-primary-sclerosing-cholangitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →